Company profile

Found

Metabolic Health & Nutrition

Company profile

About Found

Found is a telehealth weight loss company that delivers personalized, medication-assisted weight care programs designed by experts in obesity medicine. The platform provides members with access to board-certified clinicians who prescribe and manage GLP-1 medications such as compounded tirzepatide, compounded semaglutide, Wegovy, Zepbound, Mounjaro, and Ozempic, along with other weight loss medications like Metformin. Found's comprehensive approach combines prescription medication with behavioral support, lifestyle coaching, and an AI health companion called Aimee. The company serves over 300,000 members and accepts insurance from major providers across most U.S. states, with copays typically under $30 per visit for insured members. Cash-pay options are also available. Found's program is built on a proprietary metabolic health assessment called MetabolicPrint, which helps clinicians create personalized treatment plans. Members receive ongoing support through monthly check-ins with providers, 24/7 access to their care team, and a supportive member community. The company reports that members lose an average of 12% body weight after one year, with 83% sustaining results long-term. Found also partners with health plans and employers to provide weight care programs that aim to improve health outcomes while managing GLP-1 medication costs. The company's mission is to transform how society treats, manages, and talks about weight by making doctor-designed weight loss accessible for everyone.

Company description Found official website

Primary marketMetabolic Health & Nutrition
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Found?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • Back pain
  • Diabetes
  • High blood pressure
  • High cholesterol
  • Joint pain
  • Metabolic health conditions
  • Obesity
  • Overweight
  • Sleep apnea

Who it serves

  • Direct-to-consumer
  • Employers
  • Health plans

Deployment & integration

Cloud Saas deployment with recorded integration context.

Geographic context

MarketsUnited States - available in Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin, Wyoming
Company sourceOfficial website

Company milestones

Platform expansion

Serves over 300,000 members. Launched Foundayo (orforglipron) medication option. Introduced GLP-1 microdosing program. Expanded insurance coverage to 1 in 3 Americans.

Partnerships

Recorded partners

  • Employers
  • Health plans
  • Major insurance providers across most U.S. states

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

Aimee AI Health Companion

24/7 AI weight loss and lifestyle concierge

Software · Cloud SaaSCompany source

Found for Health Plans

B2B weight care program for health plans and employers

Platform · Cloud SaaSCompany source

Found Weight Loss Program

Personalized weight loss program with GLP-1 medications and comprehensive care

Platform · Cloud SaaSCompany source

Foundayo

Orforglipron-based weight loss medication option

Service · Cloud SaaSCompany source

GLP-1 Microdosing Program

Simplified way to start GLP-1 medication with lower doses

Service · Cloud SaaSCompany source

MetabolicPrint

Personalized metabolic health assessment tool

Software · Cloud SaaSCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

12% average body weight loss

at 1 year for users reporting weight weekly

3.7 BMI point reduction

at 12 months

83% member retention

sustaining results for one year

6% weight loss

at month 3 by almost half of members

$2,782 estimated annual savings

per patient with diabetes

$1,132 estimated annual savings

per patient with mental health disorders

$1,069 estimated annual savings

per patient with back pain

67% monthly participation rate

versus 20% average for employee wellness programs

1.4M pounds lost

by Found members total

Christie

Consistent weight loss

49 lbs lost through consistency

Colleen

Weight loss and life transformation

280 lbs lost - best version of myself in over 20 years

Jessica

Weight loss and sleep apnea resolution

120 lbs lost, no longer has sleep apnea, sleeping much better

Lupe

Weight loss and life improvement

43 lbs lost - huge difference in life

Mima

Finding missing link in weight loss journey

35 lbs lost - found the missing link in life

Nicole

Weight loss and quality of life improvement

80 lbs lost - living a more productive, happy, and full life

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

06 · Company updates

Updates from Found

Recent articles published on Found's official website.

No Company updates are currently listed.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

Mayo Clinic Study Reveals How Genetic Testing Is Rewriting Pulmonary Fibrosis Care Protocols

Integration of telomere length analysis and genetic sequencing into routine practice is changing diagnoses and treatment decisions for lung disease patients

Read on HAIC

India Launches Unified Drug Database to Power Next-Generation Healthcare AI

New national registry standardizes pharmaceutical data across the world's most populous nation, creating infrastructure for AI-driven clinical tools and medication safety systems.

Read on HAIC

RNA-Targeting Breakthrough: Ionis Scores Dual Wins with First-Ever FCS Therapy and $430M Licensing Deal

FDA approval of Tryngolza for ultra-rare pancreatitis disorder and major partnership for hereditary angioedema treatment signal growing confidence in antisense oligonucleotide technology.

Read on HAIC

Mountain Towns Band Together to Crack the Code on Rural Mental Health Crisis

Pooling mental health data across twelve isolated mountain communities reveals hidden behavioral health crises driven by seasonal work instability and geographic isolation.

Read on HAIC

Why the FDA Is Betting on Biology-Driven AI to Fix Drug Development's $2 Billion Failure Problem

Mechanistic AI that explains *why* drugs work—rather than just predicting outcomes—could finally give regulators the transparency needed to accelerate drug development and reduce catastrophic trial failures.

Read on HAIC

Veterans Health Data Reveals Unexpected Heart Protection from Updated COVID Boosters

Analysis of 2.3 million veterans reveals the updated vaccine formulation may offer unexpected cardiovascular protection alongside infection prevention benefits.

Read on HAIC

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Metabolic Health & Nutrition

Companies using AI to optimize metabolic health, provide personalized nutrition recommendations, or analyze metabolic responses to food for generally healthy or non-diabetic populations. Emphasizes wellness, performance optimization, and preventive health rather than management of a diagnosed disease.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon